On November 6, 2018, “The cancer-preventing HPV vaccine a dozen years on: Progress, fear, and loathing” ran in the Philadelphia Inquirer:
“A dozen years after the debut of the HPV vaccine, its track record of warding off infections that cause cervical cancer and other malignancies keeps getting better.”
“But, ironically, this powerful cancer-prevention tool also faces growing fear and rejection, stoked by anti-vaccine activism.”
Below, Dr. Read more.
Cooper University Health Care Chairman George E. Norcross, III today announced the health system will increase the minimum wage it pays employees to $15 an hour, the first health system in New Jersey to make such a commitment to its full-time, part-time, and per-diem employees. The new minimum wage policy will go into effect on January 1, 2019, and will benefit approximately 10 percent of Cooper’s 7,500 employees, one third of whom are Camden city residents and over 450 of whom are Camden County residents. Read more.
Cooper University Health Care and Advanced Recovery Systems (ARS), which operates addiction and substance abuse treatment centers in five states, announced the joining of forces to form a partnership to provide addiction recovery services to patients in the region. Together, ARS and Cooper are building a state-of-the-art, $27 million, 90-bed inpatient treatment facility in Cherry Hill, New Jersey; the first of several planned treatment facilities in the region. Read more.
MD Anderson Cancer Center at Cooper has joined a clinical research study to determine if certain breast cancer patients who respond positively to neoadjuvant systemic therapy can be treated without surgery. This study, done in conjunction with The University of Texas MD Anderson Cancer Center in Houston, is led by principal investigator Henry M. Read more.
Cooper University Health Care is one of only 24 sites in the United States currently treating patients with central sleep apnea (CSA) with a new implantable device to stimulate breathing. The remedē® System, developed by medical technology company Respicardia, Inc., received FDA-approval in 2017 and is the first commercially available device to treat CSA.
“CSA is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health,” said John A. Read more.
On Tuesday, October 9, 2018, a team from Cooper’s Infection Prevention department visited the Cathedral Kitchen in Camden. Led by Shahrzad Darvish, MSN, RN, CIC, the team volunteered to plate and serve dinner to 330 guests that evening, as well as clean-up assignments after dinner.
“It was lots of fun and everyone felt good,” said Darvish. “The volunteer in charge was impressed to see a department from Cooper health helping out; they wanted to know what we do and who we are. Read more.
MD Anderson Cancer Center at Cooper has received a three-year approval to establish a new Breast Surgical Oncology Fellowship Program by the Society of Surgical Oncology, one of fewer than 50 programs in the nation.
“Receiving approval from the Society of Surgical Oncology for this new fellowship affirms the quality of the curriculum and the faculty at MD Anderson at Cooper,” said Kristin L. Read more.
The results of a five-year, international multicenter trial studying the efficacy of a “blood purification” technique to treat sepsis has been published today in The Journal of the American Medical Association, a leading medical journal. Cooper University Health Care was the flagship investigative center and also the coordinating center for the study. Read more.
On Friday, September 21, 2018, MD Anderson Cancer Center at Cooper in conjunction with U.S. Congressman Donald Norcross (NJ-01) participated in the Biden Cancer Community Summit to hear local perspectives on treatment, proposals for federal actions, and personal stories from a panel of cancer survivors, family caregivers, doctors, and nurses.
“In this midst of our daily work, it’s important to pause and discuss these vital issues. Read more.